We welcome the correspondence from Radhakrishnan and Gartel regarding our recent Review1, which identifies the miscitation of a cell line used in their study2; however, this technicality does not distract from our inference that transformed cells are more sensitive to siomycin A-induced apoptosis than non-transformed counterparts.
We feel that the mechanism of action of thiazole antibiotics may be more complex than currently appreciated, and although we principally agree that the hypothesis described by the authors may in part account for the action of siomycin A, a complete model is currently lacking. In particular, we highlight the need to determine whether treatment of non-transformed cells with siomycin A also leads to a reduction in FOXM1 (also known as trident) expression or phosphorylation; this has not currently been described and might have important implications for the mechanism of action of siomycin A. The authors point to the existence of a positive feedback loop in vivo whereby siomycin A downregulates the expression of FOXM1 through inhibition of FOXM1 transcriptional activity, which qualifies the rationale that the effect of siomycin A upon FOXM1 protein level is not direct, but requires alteration in the expression of FOXM1, potentially through modulation of gene transcription. Moreover, after revisiting the original publication2 we feel that the physiological significance of a FOXM1 auto-regulatory loop requires further validation and may potentially reflect a cell cycle effect of FOXM1 overexpression. Although absence of proof is not proof of absence, we remain open-minded regarding the mechanism of action of these compounds, and look forward to future advances in the field. In particular, thaizole-related compounds might provide a useful tool to explore the hypothesis, described in our Review, that cancer cells may become addicted to high levels of expression or activity of FOXM1.
Debate aside, we are pleased that the authors reiterate our conclusion that FOXM1 represents an exciting and promising target for therapeutic intervention in cancer. Indeed, recent evidence suggests that FOXM1 might have a role in the invasion and angiogenesis of pancreatic cancer3, and that FOXM1 might also be a crucial mediator of transcription factor AP-2 γ (TFAP2C)-controlled oestrogen receptor α (ESR1) expression4, reinforcing the role of FOXM1 in hormonal response in patients with breast cancer. Thus, the gathering evidence suggests a scenario whereby enhanced FOXM1 expression or activity promotes three key features of cancer — cell transformation, tumour progression and metastasis — and that FOXM1 is a trident indeed.
References
Myatt, S. S. & Lam, E. W. The emerging roles of forkhead box (Fox) proteins in cancer. Nature Rev. Cancer 7, 847–859 (2007).
Radhakrishnan, S. K. et al. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 66, 9731–9735 (2006).
Wang, Z., Banerjee, S., Kong, D., Li, Y. & Sarkar, F. H. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 67, 8293–8300 (2007).
Woodfield, G. W., Horan, A. D., Chen, Y. & Weigel, R. J. TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling. Cancer Res. 67, 8439–8443 (2007).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Myatt, S., Lam, EF. Targeting FOXM1. Nat Rev Cancer 8, 242 (2008). https://doi.org/10.1038/nrc2223-c2
Issue Date:
DOI: https://doi.org/10.1038/nrc2223-c2
This article is cited by
-
MicroRNAs and angiogenesis: a new era for the management of colorectal cancer
Cancer Cell International (2021)
-
Circ-RNF121 regulates tumor progression and glucose metabolism by miR-1224-5p/FOXM1 axis in colorectal cancer
Cancer Cell International (2021)
-
Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment
Signal Transduction and Targeted Therapy (2021)
-
Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1
npj Breast Cancer (2020)
-
Forkhead box M1 transcription factor: a novel target for pulmonary arterial hypertension therapy
World Journal of Pediatrics (2020)